These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 14724543)

  • 1. [Liposomal doxorubicin and palmoplantar erythrodysesthesia].
    Tomb R; Stephan F; Halaby G
    Ann Dermatol Venereol; 2003 Nov; 130(11):1057-8. PubMed ID: 14724543
    [No Abstract]   [Full Text] [Related]  

  • 2. Hand-foot syndrome.
    Pike K
    Oncol Nurs Forum; 2001; 28(10):1519-20. PubMed ID: 11759299
    [No Abstract]   [Full Text] [Related]  

  • 3. "Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome".
    Von Moos R; Cathomas R
    Eur J Dermatol; 2009; 19(3):264-5. PubMed ID: 19213658
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe palmoplantar erythrodysesthesia and intertrigolike eruption induced by polyethylene glycol-coated liposomal doxorubicin.
    Campanelli A; Kerl K; Lübbe J
    J Eur Acad Dermatol Venereol; 2006 Sep; 20(8):1022-4. PubMed ID: 16922969
    [No Abstract]   [Full Text] [Related]  

  • 5. Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.
    Mangana J; Zipser MC; Conrad C; Oberholzer PA; Cozzio A; Knuth A; French LE; Dummer R
    Eur J Dermatol; 2008; 18(5):566-70. PubMed ID: 18693162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
    Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
    Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palmar-plantar erythrodysaesthesia and non-pegylated liposomal doxorubicin. A case study.
    Tamayo-Orbegozo E; Iruin-Sanz A; Oñate-Muzás E; Segrelles-Bellmunt G
    Farm Hosp; 2011; 35(1):46-7. PubMed ID: 20619714
    [No Abstract]   [Full Text] [Related]  

  • 9. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
    Rossi D; Catalano G
    Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894
    [No Abstract]   [Full Text] [Related]  

  • 10. Hand-foot syndrome related to liposomal doxorubicin.
    Swenson KK; Bell EM
    Oncol Nurs Forum; 2010 Mar; 37(2):137-9. PubMed ID: 20189920
    [No Abstract]   [Full Text] [Related]  

  • 11. Histologic patterns of polyethylene glycol-liposomal doxorubicin-related cutaneous eruptions.
    Cady FM; Kneuper-Hall R; Metcalf JS
    Am J Dermatopathol; 2006 Apr; 28(2):168-72. PubMed ID: 16625083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
    Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
    Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced palmer planter erythrodysesthesia.
    Bhasin S; Sunita ; Gupta DK; Kataria SP; Saluja S; Sharma M
    J Assoc Physicians India; 2005 Feb; 53():155-6. PubMed ID: 15847041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
    Risum S; Langer SW
    Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma.
    Molpus KL; Anderson LB; Craig CL; Puleo JG
    Gynecol Oncol; 2004 May; 93(2):513-6. PubMed ID: 15099971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distal phalange necrosis: a severe manifestation of palmar plantar erythrodysesthesia.
    Palaia I; Angioli R; Bellati F; Basile S; Rabitti C; Panici PB
    Am J Obstet Gynecol; 2006 Oct; 195(4):e1-2. PubMed ID: 16875651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia.
    Kanis M; Kesterson JP; Lele S
    Eur J Gynaecol Oncol; 2009; 30(4):387-8. PubMed ID: 19761128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced palmoplantar erythrodysesthesia in a child with Burkitt lymphoma.
    Saha R; Jain S; Naithani R; Kapoor G
    Pediatr Blood Cancer; 2009 Oct; 53(4):682. PubMed ID: 19489054
    [No Abstract]   [Full Text] [Related]  

  • 19. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia.
    Martschick A; Sehouli J; Patzelt A; Richter H; Jacobi U; Oskay-Ozcelik G; Sterry W; Lademann J
    Anticancer Res; 2009 Jun; 29(6):2307-13. PubMed ID: 19528496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ["Hand-foot" syndrome--after liposomal pegylated doxorubicin in patients with the ovarian cancer recurrence (own experiences)].
    Mrochen-Domin I; Nowara E; Kaleta B
    Ginekol Pol; 2008 May; 79(5):332-7. PubMed ID: 18624107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.